Families across the U.S. are facing devastating Medicaid cuts to autism therapy, jeopardizing their children's progress. Aubreigh Osborne's story highlights the urgent need for accessible treatment.
In a groundbreaking move, President Trump has forged agreements with major pharmaceutical companies to significantly lower drug prices for Americans, ensuring access to affordable medications for chronic conditions.
A proposed rule by Health Secretary Robert F. Kennedy Jr. could shut down non-compliant hospitals, impacting gender treatment for minors. With nearly half of U.S. hospitals dependent on federal funding, this move raises serious concerns.
The Trump administration is poised to announce measures effectively banning gender-affirming care for transgender minors, following recent legislative actions. Key health officials will unveil rules impacting Medicaid funding and hospital practices.
In a groundbreaking move, President Trump announces deals with Eli Lilly and Novo Nordisk to reduce obesity drug prices, making treatments more accessible for millions of Americans. Medicare coverage for GLP-1 drugs starts in 2026, changing the landscape of obesity treatment.
Despite a recent colon cancer surgery, 75-year-old James Phipps is determined to join the No Kings protests, standing against corporate greed and advocating for healthcare rights. His lifelong commitment to civil rights fuels his activism amid today's struggles.
Amid a government shutdown, President Trump promises to ensure military personnel are paid on October 15, directing the Defense Department to utilize available funds, despite political tensions.
In a major move against high prescription costs, AstraZeneca has agreed to sell its drugs at a discount through Medicaid, marking a significant win for the Trump administration's healthcare initiative.
AstraZeneca partners with the Trump administration to offer drastically lower drug prices through Medicaid and the upcoming TrumpRx platform, aiming to make medications more accessible to consumers.
In a significant announcement, President Trump is set to reveal a new drug pricing deal with AstraZeneca, following a similar agreement with Pfizer. This move aims to lower U.S. drug prices and pressure major drugmakers to bring manufacturing back to America. Will it lead to real savings for taxpayers?